These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Dec. 24 through Dec. 30, 2020. Source: InsiderScore.com
Harbert Management reported holding 5,620,681 shares of the bioscience firm, equal to 11.7% of the outstanding stock. Harbert Management addressed a letter to Enzo Biochem’s board, specifically to directors Mary Tagliaferri and Ian Walters, who were appointed to the board in November. Harbert Management believes removing Chairman and CEO Elazar Rabbani is necessary to regain confidence in Enzo Biochem. Further, Harbert suggested that a sale of Enzo Biochem would be the best way to maximize shareholder value.
Viex Capital reported a fresh 6.7% interest in the diversified social-media company, home to brands including eHow and Livestrong.com. Viex Capital bought 2,311,645 Leaf Group shares from Dec. 10 through Dec. 23 at prices ranging from $4.30 to $4.74 each. Those purchases include a Dec. 23 block-trade purchase of 1.2 million Leaf Group shares at $4.30 apiece. Viex Capital revealed nothing more other than that Leaf Group “represented an attractive investment” and offered no plans or proposals for the company.
Increases in Holdings
Ancora Advisors disclosed a higher stake in the freight and logistics firm of 1,450,048 shares, including those held personally by Ancora representatives. Ancora Advisors bought a total of 518,497 Forward Air shares from Oct. 26 through Dec. 28 at prices ranging from $60.33 to $76.75 each. Ancora now owns a 5.3% interest in Forward Air and revealed that it “has engaged and intends to continue to engage” Forward Air in ways to increase shareholder value. The discussions with the company have involved, says Ancora, “divesting of non-core assets” as well as changing the current makeup of Forward Air’s board.
Coliseum Capital Management reported a higher stake in the maker of home and work interior construction products. Coliseum now owns 3,887,142 GMS shares after buying 635,067 shares from Nov. 30 through Dec. 23 at prices ranging from $27.10 to $31.30 apiece. Following the new purchases, Coliseum now owns 9.1% of GMS’ tradable stock.
Decreases in Holdings
683 Capital Management reported a lower holding of the global reinsurance company of 7.7 million shares. 683 Capital sold 176,964 Maiden shares at prices ranging from $2.13 through $2.39 apiece from Nov. 23 through Dec. 23, leaving the investment firm owning 9.1% of Maiden’s outstanding stock.
Read More: Enzo Biochem, Leaf Group See Activist Action